Min Zhong

Summary

Publications

  1. doi 2-Aminobenzimidazoles as potent Aurora kinase inhibitors
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 19:5158-61. 2009
  2. ncbi TGR5 as a therapeutic target for treating obesity
    Min Zhong
    Presidio Pharmaceuticals, Inc, 1700 Owens Street, Suite 585, San Francisco, CA 94158, USA
    Curr Top Med Chem 10:386-96. 2010
  3. doi Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 20:5269-73. 2010
  4. doi Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 21:307-10. 2011
  5. doi Discovery of a potent and selective aurora kinase inhibitor
    Johan D Oslob
    Medicinal Chemistry, Sunesis Pharmaceuticals, 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 18:4880-4. 2008
  6. doi Water-soluble prodrugs of an Aurora kinase inhibitor
    Johan D Oslob
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 19:1409-12. 2009
  7. ncbi Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1
    Wenjin Yang
    Departments of Chemistry, Biochemistry, and Structural Biology, Sunesis Pharmaceuticals Incorporated, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 49:839-42. 2006
  8. ncbi Allosteric inhibition of protein tyrosine phosphatase 1B
    Christian Wiesmann
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Nat Struct Mol Biol 11:730-7. 2004

Collaborators

Detail Information

Publications8

  1. doi 2-Aminobenzimidazoles as potent Aurora kinase inhibitors
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 19:5158-61. 2009
    ....
  2. ncbi TGR5 as a therapeutic target for treating obesity
    Min Zhong
    Presidio Pharmaceuticals, Inc, 1700 Owens Street, Suite 585, San Francisco, CA 94158, USA
    Curr Top Med Chem 10:386-96. 2010
    ..This review briefly describes the biological rationale of TGR5 as an attractive therapeutic target and summarizes some recent efforts on the development of TGR5 modulators...
  3. doi Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 20:5269-73. 2010
    ..Either intravenous administration of 6q or oral administration of its ethyl ester (6t) produced a significant reduction of neutrophil migration in a thioglycollate-induced murine peritonitis model...
  4. doi Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists
    Min Zhong
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 21:307-10. 2011
    ..Improvement of potency in the Hut-78 assay in the presence of 10% human serum has also been achieved...
  5. doi Discovery of a potent and selective aurora kinase inhibitor
    Johan D Oslob
    Medicinal Chemistry, Sunesis Pharmaceuticals, 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 18:4880-4. 2008
    ..In particular, compound 21 (SNS-314) is a potent and selective Aurora kinase inhibitor that exhibits significant activity in pre-clinical in vivo tumor models...
  6. doi Water-soluble prodrugs of an Aurora kinase inhibitor
    Johan D Oslob
    Sunesis Pharmaceuticals, Inc, 395 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 19:1409-12. 2009
    ..In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents...
  7. ncbi Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1
    Wenjin Yang
    Departments of Chemistry, Biochemistry, and Structural Biology, Sunesis Pharmaceuticals Incorporated, 341 Oyster Point Boulevard, South San Francisco, CA 94080, USA
    J Med Chem 49:839-42. 2006
    ..The AE isostere class represents a promising advance in the development of BACE-1 inhibitors...
  8. ncbi Allosteric inhibition of protein tyrosine phosphatase 1B
    Christian Wiesmann
    Sunesis Pharmaceuticals, 341 Oyster Point Boulevard, South San Francisco, California 94080, USA
    Nat Struct Mol Biol 11:730-7. 2004
    ..Allosteric inhibition is a promising strategy for targeting PTP1B and constitutes a mechanism that may be applicable to other tyrosine phosphatases...